<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02483312</url>
  </required_header>
  <id_info>
    <org_study_id>DDP-IL-12</org_study_id>
    <secondary_id>OZM-068</secondary_id>
    <nct_id>NCT02483312</nct_id>
  </id_info>
  <brief_title>A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)</brief_title>
  <official_title>Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering Expression of IL-12</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ozmosis Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 study (the first stage in testing a new treatment to see how safe and&#xD;
      tolerable the treatment is) which will include patients with acute myeloid leukemia (AML)&#xD;
      that has either returned or has a more than a 70% chance of coming back and cannot have a&#xD;
      bone marrow transplant.&#xD;
&#xD;
      This study will see whether modifying a patient's AML cells to produce IL-12 and giving it&#xD;
      back to the patient is safe and useful in patients with AML that cannot have bone marrow&#xD;
      transplants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of side effects by type and severity</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of IL-12</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of acute myeloid leukemia (AML)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of time patient is alive</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>IL-12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of IL-12, given intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-12</intervention_name>
    <arm_group_label>IL-12</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with AML and &gt;=18 years of age.&#xD;
&#xD;
          -  Agrees to participate in the study and signs the informed consent&#xD;
&#xD;
          -  Viable cells are available for successful modification&#xD;
&#xD;
          -  First or higher complete remission and have high risk features of relapse.&#xD;
&#xD;
          -  Patients who have received prior treatment and are not in remission must have stable&#xD;
             white blood cell count and are not receiving any chemotherapy or desiring further&#xD;
             intensive treatment.&#xD;
&#xD;
          -  Less than 10% blast cells in the bone marrow following induction or re-induction&#xD;
             therapy and not desiring further intensive treatment.&#xD;
&#xD;
          -  Acceptable creatinine, Aspartate transaminase (AST), Alkaline phosphatase (ALP),&#xD;
             bilirubin lab results.&#xD;
&#xD;
          -  Agree to use contraception&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Able to comply with study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &gt;2&#xD;
&#xD;
          -  Known persistent infection&#xD;
&#xD;
          -  Known central nervous system (CNS) disease&#xD;
&#xD;
          -  Greater than 10% blasts in the bone marrow or circulating blast cells&#xD;
&#xD;
          -  Life expectancy &lt; 2 months&#xD;
&#xD;
          -  Receiving any chemotherapy, corticosteroids, Cox2 inhibitors or any non-drug therapies&#xD;
             with the intent of altering the immune response or kill leukemic cells within one week&#xD;
             prior to infusion of IL-12, except azacytidine.&#xD;
&#xD;
          -  Patients who are HIV positive.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Minden, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Minden, M.D.</last_name>
    <phone>416-946-2838</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Princess Margaret Centre Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Minden, M.D.</last_name>
      <phone>416-946-2838</phone>
    </contact>
    <investigator>
      <last_name>Mark Minden, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2015</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

